The concept that a pneumococcal cell may produce more than one capsular antigen is not new. The possible occurrence of the phenomenon was considered as early as 1928 by Griffith (1), who described, in his original report of the transformation reaction, a strain of pneumococcns agglutinated specifically by antisera to two different pneumococcal types. In the same year, the serologic cross-reactivity between pneumococcus Type III and a strain classified later as pneumococcus Type VIII was recognized (2, 3). It was shown subsequently by Goebel (4), however, that the immunologic relationship between these two capsular types resulted from the presence in their respective capsular polysaccharides of a common chemical subgroup rather than from the production by each type of several discrete capsular antigens, one of which was common to both. Similar immunologic cross-reactivity has been demonstrated among a number of other pneumococcal types (5), but in no instance has it been shown conclusively that an organism of this species produces more than one molecular type of capsular polysaccharide.
The concept that a pneumococcal cell may produce more than one capsular antigen is not new. The possible occurrence of the phenomenon was considered as early as 1928 by Griffith (1), who described, in his original report of the transformation reaction, a strain of pneumococcns agglutinated specifically by antisera to two different pneumococcal types. In the same year, the serologic cross-reactivity between pneumococcus Type III and a strain classified later as pneumococcus Type VIII was recognized (2, 3) . It was shown subsequently by Goebel (4) , however, that the immunologic relationship between these two capsular types resulted from the presence in their respective capsular polysaccharides of a common chemical subgroup rather than from the production by each type of several discrete capsular antigens, one of which was common to both. Similar immunologic cross-reactivity has been demonstrated among a number of other pneumococcal types (5) , but in no instance has it been shown conclusively that an organism of this species produces more than one molecular type of capsular polysaccharide.
In 1953, Leidy, Hahn, and Alexander (6) reported on the production in vitro of new types of Hemophilus influenzae obtained by transforming capsulated or non-capsulated organisms of this species with deoxyribonucleates (DNA) derived from bacterial cells of heterologons capsular type. Organisms reacting with each of two unitypic anticapsular sera were isolated and, although definitive experiments are not described, it is possible that these cells were producing capsular polysaccharides of two molecular species. Analogous experiments performed with pneumococcus have led to the isolation of a variety of phenotypes manifesting binary capsulation. In this and in subsequent reports, some of their biological, biochemical, and genetic properties will be set forth.
• This investigation was supported in part by research grant E-1018(C2) from the Institute of Allergy and Infectious Diseases, United States Public Health Service.
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Materials and Methods
Nomenclature of Pneumococcal Variants.--In certain of the pneumococcal strains to be described, there is lack of complete correspondence between phenotype and genotype. For this reason, complexities arise in the description of these strains. For the present, only phenotypic designations will be employed and terms descriptive of genotype will be introduced later.
Fully capsulated phenotypes are indicated by the letter S followed by a Roman numeral designating capsular type; e.g., SIII is a capsulated strain of pneumococcus Type IlI. Because of certain biochemical relationships to be described subsequently and for convenience, non-capsulated variants and intermediate capsular variants agghitinable by antibody to somatic antigens, including those described by Taylor (7) under the term SIII-1, will be designated by the expression S-xt, the subscript designating the capsular type from which the mutant strain was derived and the strain's designation; e.g., S--III~ is Strain 4 of a non-capsulated phenotype derived from pneumococcus Type III. Phentotypes manifesting binary capsulation will be indicated by the letter S followed by the two Roman numerals descriptive of the strain's capsular components separated by a hyphen; e.g., SI-III is a pneumococcus characterized by the production of both Type I and Type III capsular polysaecharides. 
Strains of
Preparation of DNA (Transforming Principles) and Technique of Transformation Re-
aa/ons.--The methods used were those described by MacLeod and Krauss (9) .
Preparation of Anticapsular Sera.--Vaecines of unitypic pneumococd and of pneumococci producing two capsular polysaccharides were prepared from cultures grown at 37°C. for 12 to 16 hours. After standing for I hour at room temperature following the addition of neutralized formalin to a final concentration of 1 per cent, the organisms were collected by centrifugation and resuspended in a volume of normal saline solution one-tenth that of the original culture. The suspendon was heated at 65°C. for 30 minutes and stored at 4°C. Rabbits were immunized by the injection intravenously of 1 co. of vaccine daily for 5 days and were bled on the 10th day following each course of vaccine.
Precipitin Tests.--Precipitin tests were carried out in small test tubes. 0.2 cc. of each of several serial dilutions of antigen was layered over 0.2 ce. of serum. The tubes were incubated for 1 hour at 37°C. and the reactions read after the tubes had stood overnight at 4°C.
Precipitin reactions in agar gels were carried out according to the technique of Ouehterlony as modified by Halbert (10) .
Virulence and Protection
Tests.--Tests of virulence were performed by the injection intraperitoneally into mice of the CFW strain of 1 ec. of an appropriate dilution of a blood broth culture of the strain to be tested which had been incubated for 16 hours. Counts of viable bacterial units were obtained by dilution and plating. In protection tests, mice were injected intraperitoneally with 1 cc. of the serum to be tested 24 hours before being infected with pneumococci as in tests of virulence. Control animals received normal rabbit serum. All tests were continued for 10 days and results were scored in terms of survival or death. The cause of death was determined by culture of the animal's blood at autopsy. In experiments in which the enzyme which hydrolyzes specifically Type III capsular polysaccharide I was employed, 2 nag. of enzyme were injected intraperitoneaUy.
Tests (Table I) .
SI-III cells were observed first in experiments in which strain S-HI, had been exposed to DNA from a capsulated Type I strain. In quellung preparations, ~ it was noted that the transformed cells showed capsular swelling when exposed either to Type I or to Type III antiserum. The size of the refractile capsular halo in Type HI antiserum was approximately that seen about cells of the normally capsulated Type HI phenotype but the refractile zone about cells in Type I antiserum was distinctly smaller than that about capsulated Type I cells and at times could be seen only with difficulty. Variation in the size of the two capsular components in relation to the phase of bacterial growth was not observed. When the cells manifesting b;nary capsulation were exposed to a mixture of Type I and Type III antisera, the capsular swelling was not recognizably greater than that which followed contact with Type III antiserum alone. In smears stained by the Gram technique, such cells showed no consistent variation in size or in shape which permitted their distinction from singly capsulated variants. SI-III cells isolated from the peritoneal cavity of the white mouse did show elongated forms often in short chains, morphologic characteristics not manifested by the organism when grown in vitro.
On solid medium, SI-III cells give rise to clones morphologically indistinguishable from those formed by pneumococcus Type III, a not surprising finding in view of the significant amount of Type III polysaccharide formed by the SLIII cell.
Evidence Establishing the Existence of the SI-III CelL--The observation that more than 90 per cent of cells from clones of the SI-III phenotype gave a positive quellung reaction in both Type I and Type III anticapsular serum provided strong presumptive evidence for the existence of a cell producing two capsular polysaccharides or one so constituted chemically as to possess the serologically reactive groups of Type I and of Type III polysaccharide.
To distinguish between cells manifesting binary capsulation and mixtures of SI and SIII cells, several types of experiment were performed. Table II shows the results of growing SI, SIII, mixtures of SI and SIII cells and SI-III cells in broth containing either Type I or Type HI anticapsular serum. Only those cells producing simultaneously two capsular polysaccharides are agglutinated by both Unitypic antisera and yield cultures with limpid supematant fluids in the presence of each antiserum in so called "thread tests."
Similar evidence distinguishing cells with binary capsules from unitypic cells has been obtained from mouse protection tests. The evidence in Table III indicates that all animals infected with cells with binary capsules were protected by either unitypic capsular antiserum whereas none was protected by either 
Medium: neopeptone broth plus 10 per cent anticapsular rabbit serum; L ffi limpid superuatant fluid. T ffi turbid supernatant fluid. ment, SI-III cells are no longer agglutinable by Type III anticapsular serum and they fail to give a quellung reaction with Type III antibody. Their agglutinability by Type I anticapsular serum remains unimpaired, however, and the treated cells give still a positive quellung reaction with Type I antibody. It has been shown that the action of the enzyme hydrolyzing Type III pneumococcal polysaccharide is more highly specific than antibody to Type HI polysaccharide. In addition, the action of this enzyme has been demonstrated recently to be that of an endoenzyme rather than that of an exoenzyme attacking the end-groups of a macromolecule (12) . The experiments suggest strongly, therefore, that the SI-III cell produces normal Type III polysaccharide or a substance resembling it very closely and one that is probably distinct from the Type I component of the capsule.
In precipitin reactions carried out in an agar gel by the modified technique of Ouchterlony (10), the precipitates formed when Type III anticapsular antibody is allowed to react in the same plate with SI-III cells, SIII cells and Type III polysaccharide give rise to a line of continuity (Fig. 1) ; and, in like manner, a line of continuity is produced when the reactants are Type I anticapsular antibody, SI-III cells and Type I polysaccharide (Fig. 2) .
Precipitin tests performed with partially purified polysaccharides from SI-III cells show that the Type III polysaccharide can be precipitated by Type III anticapsular serum without significant removal of the Type I corn- A 200 cc. culture of SI-III cells was grown overnight after which time glucose was added to a final concentration of 1 per cent. During an additional 6 hours' incubation, the lactic acid formed was neutralized by the addition of 3 N NaOH. The cells were then removed by centrifugation and 1 volume of 95 per cent ethyl alcohol was added to the separated supernatant fluid. The suspension was stored overnight at 4°C. after which time, the precipitate formed was collected by centrifugation and dissolved in 10 cc. of normal salt solution. This solution served as the unfractionated capsular antigen. Aliquots thereof were allowed to react with appropriate amounts of Type I or Type III anticapsular rabbit serum or with normal rabbit serum. All volumes were adjusted to give the same quantity of the original antigen in precipifin tests. The results are shown in Table IV. On the bases of the independent variability of its capsular components, of the susceptibility of the Type III capsular component to the enzyme hydro- itself to shift the balance of infection decisively in favor of the pneumococcus. Later, when the enzyme is no longer effective, regeneration of the Type III capsular component provides more effective protection against phagocytosis and permits rapid progression of the infection to a fatal outcome.
Phagocytosis of Sl-lll Cells by Human Polymorphonudear Leukocytes.--In
Properties of Antiserum Prepared with Vaccines of SI-III Pneumococci.--
Rabbits immunized with vaccines of pneumococci manifesting binary capsulation form antibodies to each of the capsular components of such cells. The relative amount of antibody to each of the capsular antigens may vary during the course of immunization. Antisera to SI-III cells cause capsular swelling of SI, SIII, SI-III, and SIII-V cells. Shown in Table VII is the protective effect of such antiserum in mice infected with cells of each of the aforementioned phenotypes and with mixtures of SI and SIII ceils. Recorded also in the table is the absence of protection against infection with pneumococcus Type V. Analogous results are observed in experiments concerned with the phagocytosis of pneumococci of several capsular types in the presence of Type I-III antiserum (Table VIII) .
Precipitin tests in an agar gel (Fig. 3 ) disclose several facts. First, with Type I cells and Type I capsular polysaccharide, the anti-SI-III serum forms a continuous band of precipitate, and with Type III cells and Type III capsular polysaccharide a second and distinct band is formed. Second, these lines of precipitate are continuous with those formed by the antibody reacting with each of the capsular components of the SI-III cell. Third, there is no band of precipitate formed to indicate the presence of a single species of antibody SI-III cells. That two distinct anticapsular antibodies are present in such an antiserum can be demonstrated by the independent precipitability of each. When an antiserum prepared with a vaccine of SI-III cells is absorbed with either capsulated Type I or Type III cells, the corresponding anticapsular antibody is removed without significant alteration of the titer of antibody precipitating the other capsular component (Table IX) . Analogous experiments in which precipitin reactions were carried out in an agar gel demonstrate the independent removal of one capsular antibody without alteration in the reaction of the other with appropriate antigens (Figs. 4 to 6) .
Properties of Deoxyribonucleates of Pneumococci of the SI-III Phenotype.--To
determine the nature of the genetic determinants of the capsular components of the SI-III cell, DNA was prepared from cultures of such ceils in the usual manner. When ceils of a non-capsulated pneumococcns (R36NC) derived originally from a strain of capsular Type II were exposed in the transforming system to DNA from SI-III cells, organisms of three different phenotypes were recovered: S--H~, SI and SI-III. No SIII cells were observed. The results indicate that there has been no major alteration in either of the genetic units concerned with the formation of the two capsular components of the cell manifesting binary capsulation during their residence within that cell and that each is able to engender expression of that character controlled by it when it is reintroduced as the sole genetic factor concerned with capsular formation into another pneumococcal cell.
DISCUSSION
Through the agency of the transformation reaction, it has been possible to isolate pneumococci manifesting binary capsulation of several phenotypes. Examination of cells of the SI-III phenotype in a number of experimental systems reveals that organisms of this type produce two distinct capsular polysaccharides which are closely similar if not identical to those produced by cells of the corresponding unitypic phenotypes. The evidence available suggests that the two types of polysaccharide are intermingled in the capsule in a random fashion. Study of cells of the SIII-V phenotype yields results of a similar nature.
Binary capsulation in pneumococcus provides a new basis for serologic cross-reactivity in this species. Cells manifesting binary capsulation react with unitypic antiserum to each of their capsular components and stimulate the formation of antibodies which will react with cells bearing either of the capsular antigens produced by cells of the binary capsular phenotype. Whether or not pneumococci manifesting binary capsulation exist in nature remains an unanswered question. Examination by genetic and serologic techniques of several groups of pneumococcal strains the capsular antigens of which show crossreactivity has failed to result in the recognition in any of the strains of separable capsular antigens. It would appear more likely that the serologic interrelationships of these strains are based upon the presence of common chemical subgroups in their single capsular polysaccharides rather than upon their production of multiple types of capsular polysaccharide. For this reason the nomenclature of pneumococcal types proposed by Eddy (13) seems preferable to that proposed by Kauffmann and Lund (14) .
These experiments with pneumococcns show many similarities to those performed with H. influenzae by Leidy, Hahn, and Alexander (6), and it appears probable that binary capsulation may be manifested by organisms of the latter species. In each, however, it would appear to represent a product of the laboratory. This fact notwithstanding, binary capsulation provides a useful object for the study of a variety of biologic phenomena.
SI.~r~ARY
Pneumococci manifesting binary capsulation have been produced through the agency of transformation reactions. Such cells produce two capsular polysaccharides which are closely similar if not identical with those produced by corresponding singly capsulated strains.
Binary capsulation in pneumococcns provides a new basis for serologic cross-reactivity in this species. Reactions between (A) and (F) failed to develop sufficiently to be visible in the photograph.
